RhumbLine Advisers
PSTX

RhumbLine Advisers’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

RhumbLine Advisers’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-113,431
Closed -$1.09M – 4184
2024
Q4 		$1.09M Buy
113,431
+8,931
+9% +$46.6K ﹤0.01% 2211
2024
Q3 		$299K Buy
104,500
+7,488
+8% +$23.2K ﹤0.01% 3028
2024
Q2 		$283K Buy
97,012
+3,875
+4% +$10.6K ﹤0.01% 3034
2024
Q1 		$297K Buy
93,137
+3,955
+4% +$13.2K ﹤0.01% 2984
2023
Q4 		$300K Buy
89,182
+1,985
+2% +$5.11K ﹤0.01% 2973
2023
Q3 		$208K Sell
87,197
-4,964
-5% -$10.4K ﹤0.01% 3142
2023
Q2 		$162K Buy
+92,161
New +$235K ﹤0.01% 3341
2022
Q2 		– Sell
-34,064
Closed -$153K – 3264
2022
Q1 		$153K Buy
34,064
+3,137
+10% +$14.1K ﹤0.01% 2816
2021
Q4 		$211K Sell
30,927
-516
-2% -$3.52K ﹤0.01% 2820
2021
Q3 		$229K Buy
31,443
+982
+3% +$8.43K ﹤0.01% 2861
2021
Q2 		$305K Buy
30,461
+8,301
+37% +$74.3K ﹤0.01% 2778
2021
Q1 		$212K Buy
22,160
+11,818
+114% +$116K ﹤0.01% 2819
2020
Q4 		$113K Buy
+10,342
New +$109K ﹤0.01% 2955

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RhumbLine Advisers's PSTX Position: Q1 2025 in Review

RhumbLine Advisers sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 113,431 shares — an estimated $1.09M sold.

RhumbLine Advisers first reported a position in PSTX in Q4 2020 and held it in 13 quarters. The position peaked at $1.09M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • RhumbLine Advisers reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 113,431 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.09M.
  • RhumbLine Advisers first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2020 and held it in 13 quarters.
  • RhumbLine Advisers's Poseida Therapeutics, Inc. Common Stock position peaked at $1.09M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on RhumbLine Advisers's 13F filing for Q1 2025, filed 8 Apr 2025.